Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)axicabtagene ciloleucel (INN), YESCARTA suspension for intravenous infusion (1bag (68ml)) 1 Piece　,and 11 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Jul 24, 2024
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Kagoshima
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : FUJISAWA Wataru, Executive Chief of Contract Administration, National University Corporation Kagoshima University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A axicabtagene ciloleucel (INN), YESCARTA suspension for intravenous infusion (1bag (68ml)) 1 Piece
B Pabinafusp Alfa (Genetical Recombination), IZCARGO for I.V. infusion 10㎎ (1Vial) 130 Pieces
C Satralizumab (Genetical Recombination), ENSPRYNG Syringes for Subcutaneous Injection 120㎎ (1ml×1Syringe) 27 Pieces
D Ofatumumab (Genetical Recombination), Kesimpta for s.c. injection 20㎎ pen (1Piece) 72 Pieces
E Nusinersen Sodium, SPINRAZA Intrathecal injection 12㎎ (1Vial/1Box) 21 Sets
F onasemnogene abeparvovec, zolgensma (1Patient) 1 Piece
G Avalglucosidase Alfa (Genetical Recombination), NEXVIAZYME for I.V. Infusion (1Vial) 156 Pieces
H Faricimab (Genetical Recombination), VABYSMO solution for Intravitreal Injection (0.24ml×1Vial) 145 Pieces
I Idursulfase beta (Genetical Recombination), Hunterase ICV Injection 15㎎ (1mL [1Vial]) 12 Pieces
J Emicizumab (Genetical Recombination), HEMLIBRA for Subcutaneous Injection 90㎎ (0.6ml×1Vial) 94 Pieces
K Dinutuximab (Genetical Recombination), UNITUXIN I.V. injection 17.5㎎/5mL (1Vial (5mL)) 20 Pieces
L Ravulizumab (Genetical Recombination), ULTOMIRIS for Intravenous Infusion 300㎎/3㎖ (3mL [1Vial]) 169 Pieces
⑷ Delivery period : From 1 October, 2024 through 31 March, 2025
⑸ Delivery place : Kagoshima University Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 2 and 3 of the Regulation concerning the Contract for Kagoshima University,
B have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 2024 in the Kyushu・Okinawa area in sales of product for participating in tenders by Single qualification for every ministry and agency, or have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 2024 in sales of product for participating in tenders by National University Corporation Kagoshima University,
C prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D meet the qualification requirements which Executive Chief of Contract Administration, National University Corporation Kagoshima University may specify in accordance with Article 4, section 6 of the Regulation concerning the Goods supply contract for Kagoshima University,
E not be currently under a suspension of business order as instructed by Executive Chief of Contract Administration, National University Corporation Kagoshima University.
⑺ Time limit of tender : 17 : 00 13 September, 2024
⑻ Contact point for the notice : SHIMANA Yuuichirou, Procurement Section, Administrative Division, Kagoshima University Hospital, 8-35-1 Sakuragaoka Kagoshima-shi 890-8520 Japan, TEL 099-275-5045
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.